Transitioning from learning healthcare systems to learning health care communities

Abstract

The learning healthcare system (LHS) model framework has three core, foundational components. These include an infrastructure for health-related data capture, care improvement targets and a supportive policy environment. Despite progress in advancing and implementing LHS approaches, low levels of participation from patients and the public have hampered the transformational potential of the LHS model. An enhanced vision of a community-engaged LHS redesign would focus on the provision of health care from the patient and community perspective to complement the healthcare system as the entity that provides the environment for care. Addressing the LHS framework implementation challenges and utilizing community levers are requisite components of a learning health care community model, version two of the LHS archetype.

Taiwan renal care system: A learning health‐care system

“…The learning health-care system is defined as a system in which science, informatics, incentives and culture are united for continuous improvement and innovation, with best practices implanted in the delivery process and new knowledge captured as an integral result of the delivery experience. 3 A learning health-care system routinely enables pursuit of better and safer care at lower cost, enhancement of public health and consumer empowerment. 4 The process of a learning health-care system was to collect, accumulate and analyze data, interpret results, deliver tailored message and take action to change practice ( Fig.…”

The Interface of Therapeutics and Genomics in Cardiovascular Medicine

“…nicardipine dose and CYP2C19 metaboliser status) [ 120 ]. More generally, a transition from current healthcare models to learning healthcare systems/communities that bring healthcare delivery, real-world data collection, evidence generation, implementation, and follow-up outcome monitoring all closer together into an iterative positive cycle will optimise returns on investment in genomic and other novel technologies and so improve healthcare quality, encourage patient engagement, and increase the rate of adoption of validated new findings [ 121 ]. This must be coupled with guidance from professional bodies to support prescribers in implementing pharmacogenomic tools that are currently validated for clinical use.…”

Ethics codes and use of new and innovative drugs

“…We also believe that a need for guidance about use of new and/or innovative treatments may increase as a result of the development of Learning Healthcare Systems, which promote a better integration of patient care with biomedical research to ensure innovation, quality, safety and value in healthcare .…”